Developer docs
API playgroundTry for free, no card

Search company profiles

Aecor Bio

Full company profile

uuid0000n45

Namestring
Aecor Bio
Legal namestring
AecorBio Inc.
Websiteurl
aecorbio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

AecorBio Inc. is an IND-stage biopharmaceutical company headquartered in Menlo Park, California, founded in 2023. The company has developed a proprietary high-throughput peptide drug discovery platform based on targeted protein hydrolysis (SPH) of single proteome sources, generating libraries of 10,000+ diverse peptides. Unlike conventional screening approaches that measure binding affinity, AecorBio identifies hits by measuring gene expression modulation directly, enabling discovery of novel scaffolds chemically distinct from synthetic drug libraries. The company's pipeline targets treatment resistance across oncology, immunology, and neurology, with lead asset FT-002a-O advancing toward IND filing (target Q1 2027) for Castration-Resistant Prostate Cancer by normalizing IREB2-driven iron dysregulation and restoring sensitivity to androgen receptor inhibitors.

The company's portfolio includes three preclinical/IND-enabling programs: FT-002a-O for CRPC (78% tumor reduction vs. enzalutamide alone in preclinical models, NOAEL at 2,000 mg/kg/day), a label extension into platinum-resistant ovarian cancer, MA-022s for steroid-resistant asthma and eosinophilic esophagitis, and Peptide-DRD2 for Restless Leg Syndrome and Parkinson's Disease. AecorBio operates a lean managed services model with world-class CRO, CMC, and regulatory partners, and maintains an IND-enabling clinical collaboration with Stanford University.

AecorBio is pre-revenue and does not commercialize products. Its business model is structured around future pharmaceutical licensing agreements and co-development partnerships with large pharma companies holding androgen receptor inhibitor franchises (J&J, Pfizer, Astellas, Novartis), where FT-002a would be positioned as an additive combination therapy rather than a displacement of existing blockbusters. The company has raised approximately $2.53 million through an SEC-registered offering in 2025 with 20 investors, following an earlier ~$900K seed round in 2023, and is led by CEO & Co-Founder Dr. Bomi Framroze.

Short descriptiontext

AecorBio is a preclinical biopharmaceutical company developing a proprietary high-throughput peptide drug discovery platform targeting treatment resistance mechanisms in oncology, immunology, and neurology, with lead asset FT-002a advancing toward IND filing for castration-resistant prostate cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, oncology drug discovery, prostate cancer treatment, immunology drug development, neurology therapeutics
Industry5 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Peptide Therapeutics / Biopharmaceutical Drug Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Licensing
TypeLicensing Royalties
Description

Pre-revenue preclinical stage company. Revenue model will likely involve licensing agreements and co-development partnerships with large pharmaceutical companies for their peptide therapeutics pipeline across oncology, immunology, and neurology indications.

aecorbio.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AecorBio develops novel peptide therapeutics through a proprietary high-throughput peptide drug discovery platform, with lead candidate FT-002a-O targeting treatment resistance in Castration-Resistant Prostate Cancer (CRPC). The company also has preclinical programs MA-022s (steroid-resistant asthma and EoE) and Peptide-DRD2 (Restless Leg Syndrome and Parkinson's Disease). Revenue is generated through pharmaceutical licensing and co-development partnerships with large pharma companies rather than direct product sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 78% tumor volume reduction vs enzalutamide alone in 46-day AR-resistant PC3 orthotopic CRPC model
+4 more records
Product overview1 text field

AecorBio is an IND-stage biopharmaceutical company with a novel high-throughput peptide drug discovery platform targeting multiple drug resistance mechanisms across oncology, immunology, and neurology. The company's portfolio includes multiple drug candidates: FT-002a-O is the lead IND-enabling asset for Castration-Resistant Prostate Cancer (CRPC), MA-022s is in preclinical development for steroid-resistant asthma and eosinophilic esophagitis, and Peptide-DRD2 is in optimization for Restless Leg Syndrome and Parkinson's disease. The platform itself employs targeted proteome hydrolysis to generate peptide libraries, screening for gene expression regulation rather than binding affinity.

Product and service4 records
1FT-002a-O
CategoryDrug Candidate — Oncology (Peptide Therapeutic)
Description

Orally available peptide co-therapeutic for Castration-Resistant Prostate Cancer (CRPC) that normalizes IREB2-driven iron dysregulation in treatment-resistant prostate tumors, restoring sensitivity to androgen deprivation therapy. Demonstrated 78% tumor volume reduction vs. enzalutamide (SOC) alone in a 46-day AR-resistant PC3 orthotopic CRPC model with clean safety profile at all doses tested. Target IND approval Q1 2027 with Phase 1b completion targeted for Q1 2028.

2MA-022s
CategoryDrug Candidate — Immunology (Peptide Therapeutic)
Description

Novel lipopeptide lead drug candidate for Steroid-Resistant Asthma and Eosinophilic Esophagitis (EoE) with a dual mechanism addressing both eosinophilia and non-T2 inflammatory pathways. Target IND approval Q2 2027.

3Peptide-DRD2
CategoryDrug Candidate — Neurology (Peptide Therapeutic)
Description

Novel peptide for DRD2 gene upregulation being developed as a dopamine agonist augmentation co-treatment targeting Restless Leg Syndrome and Parkinson's Disease. Target IND approval Q2 2028.

4FT-002a-O (Platinum-Resistant Ovarian Cancer Indication)
CategoryDrug Candidate — Oncology (Peptide Therapeutic)
Description

Label extension of FT-002a's mechanism of action (iron normalization) applied to platinum resistance in ovarian cancer. Targets the iron-dependent survival pathway that underpins cisplatin resistance. Target IND approval Q3 2027.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IND-enabling clinical collaboration with Stanford University. Leverages academic partnership for clinical development expertise and site access.

2Discovery and Preclinical CRO Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-class partners across discovery, preclinical CRO, CMC and regulatory strategy. Supports the company's lean, capital-efficient managed services operating model.

aecorbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage peptide therapeutics platform developing novel constrained and stabilized peptides for hematology, immunology, and oncology. Directly comparable as a peptide-discovery platform with multiple pipeline programs and similar preclinical-to-IND transition profile, though focused on different targets (hepcidin mimetics, IL-17, IL-23).

TypeDirect peer
Description

Peptide-based therapeutics company developing oral small molecule and peptide candidates for rare endocrine diseases and oncology. Comparable as a peptide therapeutics developer with multiple programs and a focus on oral peptide bioavailability, an area where AecorBio also differentiates (FT-002a achieves ~30% oral bioavailability).

TypeDirect peer
Description

Commercial-stage peptide therapeutics company targeting melanocortin-4 receptor (MC4R) pathway for rare obesity disorders. Comparable as a focused peptide therapeutics developer with strong management team and clear partnership/licensing DNA, though operating at a more advanced commercial stage.

TypeDirect peer
Description

Peptide-based therapeutics company developing melanocortin receptor-targeted peptides for sexual dysfunction, obesity, and inflammatory diseases. Comparable as a peptide therapeutics developer with similar size and multi-program pipeline approach, though at a more advanced clinical stage.

TypeDirect peer
Description

Clinical-stage biotech developing peptide conjugates for Duchenne muscular dystrophy and neurological diseases. Comparable as a peptide platform company targeting neurology indications (similar to AecorBio's Peptide-DRD2 program) with novel chemistry approaches.

TypeEmerging player
Description

Clinical-stage biotech pioneering targeted protein degradation (PROTAC) technology for oncology. Comparable as an emerging oncology company using novel protein-targeting approaches against previously undruggable mechanisms, similar positioning to AecorBio's IREB2/LIP novel target strategy.

7ESSA Pharma
TypeDirect peer
Description

Clinical-stage oncology company developing next-generation therapies for prostate cancer, particularly targeting the androgen receptor pathway in treatment-resistant prostate cancer. Direct comparison for the CRPC treatment-resistance use case that AecorBio's FT-002a addresses.

TypeDirect peer
Description

Danish peptide therapeutics company with multiple marketed products (dasiglucagon, glepaglutide) and pipeline across metabolic and rare diseases. Comparable as an established peptide platform with multi-program pipeline and licensing/co-development orientation similar to AecorBio's strategy.

TypeEmerging player
Description

Clinical-stage precision oncology company developing menin inhibitors and farnesyltransferase inhibitors for genetically defined cancers. Comparable as a mid-stage oncology company focused on novel mechanisms in solid tumors, with similar partnership/development model to AecorBio.

TypeEmerging player
Description

Late-stage biotech developing novel therapeutic peptides (lotilaner) for ophthalmic and infectious disease indications. Comparable as a peptide-based therapeutics developer with novel mechanism approaches and multi-program pipeline.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aecor Bio

Peptide Therapeutics / Biopharmaceutical Drug Developmentaecorbio.com

AecorBio is a preclinical biopharmaceutical company developing a proprietary high-throughput peptide drug discovery platform targeting treatment resistance mechanisms in oncology, immunology, and neurology, with lead asset FT-002a advancing toward IND filing for castration-resistant prostate cancer.

What Aecor Bio does

AecorBio Inc. is an IND-stage biopharmaceutical company headquartered in Menlo Park, California, founded in 2023. The company has developed a proprietary high-throughput peptide drug discovery platform based on targeted protein hydrolysis (SPH) of single proteome sources, generating libraries of 10,000+ diverse peptides. Unlike conventional screening approaches that measure binding affinity, AecorBio identifies hits by measuring gene expression modulation directly, enabling discovery of novel scaffolds chemically distinct from synthetic drug libraries. The company's pipeline targets treatment resistance across oncology, immunology, and neurology, with lead asset FT-002a-O advancing toward IND filing (target Q1 2027) for Castration-Resistant Prostate Cancer by normalizing IREB2-driven iron dysregulation and restoring sensitivity to androgen receptor inhibitors.

The company's portfolio includes three preclinical/IND-enabling programs: FT-002a-O for CRPC (78% tumor reduction vs. enzalutamide alone in preclinical models, NOAEL at 2,000 mg/kg/day), a label extension into platinum-resistant ovarian cancer, MA-022s for steroid-resistant asthma and eosinophilic esophagitis, and Peptide-DRD2 for Restless Leg Syndrome and Parkinson's Disease. AecorBio operates a lean managed services model with world-class CRO, CMC, and regulatory partners, and maintains an IND-enabling clinical collaboration with Stanford University.

AecorBio is pre-revenue and does not commercialize products. Its business model is structured around future pharmaceutical licensing agreements and co-development partnerships with large pharma companies holding androgen receptor inhibitor franchises (J&J, Pfizer, Astellas, Novartis), where FT-002a would be positioned as an additive combination therapy rather than a displacement of existing blockbusters. The company has raised approximately $2.53 million through an SEC-registered offering in 2025 with 20 investors, following an earlier ~$900K seed round in 2023, and is led by CEO & Co-Founder Dr. Bomi Framroze.

Aecor Bio firmographics

Firmographics
Name
Aecor Bio
Legal name
AecorBio Inc.
Website
https://aecorbio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
AecorBio is a preclinical biopharmaceutical company developing a proprietary high-throughput peptide drug discovery platform targeting treatment resistance mechanisms in oncology, immunology, and neurology, with lead asset FT-002a advancing toward IND filing for castration-resistant prostate cancer.
Ownership category
akta.pro rank

Aecor Bio industry classification

Industry
Product category
Peptide Therapeutics / Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Peptide therapeutics
  • Oncology drug discovery
  • Prostate cancer treatment
  • Immunology drug development
  • Neurology therapeutics

Where Aecor Bio is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aecor Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Others

Revenue model

  1. Pharmaceutical Licensing: Pre-revenue preclinical stage company. Revenue model will likely involve licensing agreements and co-development partnerships with large pharmaceutical companies for their peptide therapeutics pipeline across oncology, immunology, and neurology indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Aecor Bio product offering

Product offering

Core offering

AecorBio develops novel peptide therapeutics through a proprietary high-throughput peptide drug discovery platform, with lead candidate FT-002a-O targeting treatment resistance in Castration-Resistant Prostate Cancer (CRPC). The company also has preclinical programs MA-022s (steroid-resistant asthma and EoE) and Peptide-DRD2 (Restless Leg Syndrome and Parkinson's Disease). Revenue is generated through pharmaceutical licensing and co-development partnerships with large pharma companies rather than direct product sales.

Product overview

AecorBio is an IND-stage biopharmaceutical company with a novel high-throughput peptide drug discovery platform targeting multiple drug resistance mechanisms across oncology, immunology, and neurology. The company's portfolio includes multiple drug candidates: FT-002a-O is the lead IND-enabling asset for Castration-Resistant Prostate Cancer (CRPC), MA-022s is in preclinical development for steroid-resistant asthma and eosinophilic esophagitis, and Peptide-DRD2 is in optimization for Restless Leg Syndrome and Parkinson's disease. The platform itself employs targeted proteome hydrolysis to generate peptide libraries, screening for gene expression regulation rather than binding affinity.

Differentiator

Problem solved

Functional benefit

Products and services

  • FT-002a-O Orally available peptide co-therapeutic for Castration-Resistant Prostate Cancer (CRPC) that normalizes IREB2-driven iron dysregulation in treatment-resistant prostate tumors, restoring sensitivity to androgen deprivation therapy. Demonstrated 78% tumor volume reduction vs. enzalutamide (SOC) alone in a 46-day AR-resistant PC3 orthotopic CRPC model with clean safety profile at all doses tested. Target IND approval Q1 2027 with Phase 1b completion targeted for Q1 2028.
  • MA-022s Novel lipopeptide lead drug candidate for Steroid-Resistant Asthma and Eosinophilic Esophagitis (EoE) with a dual mechanism addressing both eosinophilia and non-T2 inflammatory pathways. Target IND approval Q2 2027.
  • Peptide-DRD2 Novel peptide for DRD2 gene upregulation being developed as a dopamine agonist augmentation co-treatment targeting Restless Leg Syndrome and Parkinson's Disease. Target IND approval Q2 2028.
  • FT-002a-O (Platinum-Resistant Ovarian Cancer Indication) Label extension of FT-002a's mechanism of action (iron normalization) applied to platinum resistance in ovarian cancer. Targets the iron-dependent survival pathway that underpins cisplatin resistance. Target IND approval Q3 2027.

Quantifiable outcome

  • 78% tumor volume reduction vs enzalutamide alone in 46-day AR-resistant PC3 orthotopic CRPC model
  • +4 more outcomes

Companies that use Aecor Bio

Customer profile

Segments4 records

Ideal customer profiles2 records

Aecor Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aecor Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Stanford UniversitycoreStrategic or Co-development PartnerIND-enabling clinical collaboration with Stanford University. Leverages academic partnership for clinical development expertise and site access.
  • Discovery and Preclinical CRO PartnerscoreStrategic or Co-development PartnerWorld-class partners across discovery, preclinical CRO, CMC and regulatory strategy. Supports the company's lean, capital-efficient managed services operating model.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Aecor Bio competitors and assessment

Company assessment

Direct peers

  • Protagonist Therapeutics: Clinical-stage peptide therapeutics platform developing novel constrained and stabilized peptides for hematology, immunology, and oncology. Directly comparable as a peptide-discovery platform with multiple pipeline programs and similar preclinical-to-IND transition profile, though focused on different targets (hepcidin mimetics, IL-17, IL-23).
  • Crinetics Pharmaceuticals: Peptide-based therapeutics company developing oral small molecule and peptide candidates for rare endocrine diseases and oncology. Comparable as a peptide therapeutics developer with multiple programs and a focus on oral peptide bioavailability, an area where AecorBio also differentiates (FT-002a achieves ~30% oral bioavailability).
  • Rhythm Pharmaceuticals: Commercial-stage peptide therapeutics company targeting melanocortin-4 receptor (MC4R) pathway for rare obesity disorders. Comparable as a focused peptide therapeutics developer with strong management team and clear partnership/licensing DNA, though operating at a more advanced commercial stage.
  • Palatin Technologies: Peptide-based therapeutics company developing melanocortin receptor-targeted peptides for sexual dysfunction, obesity, and inflammatory diseases. Comparable as a peptide therapeutics developer with similar size and multi-program pipeline approach, though at a more advanced clinical stage.
  • PepGen: Clinical-stage biotech developing peptide conjugates for Duchenne muscular dystrophy and neurological diseases. Comparable as a peptide platform company targeting neurology indications (similar to AecorBio's Peptide-DRD2 program) with novel chemistry approaches.
  • ESSA Pharma: Clinical-stage oncology company developing next-generation therapies for prostate cancer, particularly targeting the androgen receptor pathway in treatment-resistant prostate cancer. Direct comparison for the CRPC treatment-resistance use case that AecorBio's FT-002a addresses.
  • Zealand Pharma: Danish peptide therapeutics company with multiple marketed products (dasiglucagon, glepaglutide) and pipeline across metabolic and rare diseases. Comparable as an established peptide platform with multi-program pipeline and licensing/co-development orientation similar to AecorBio's strategy.

Emerging players

  • Arvinas: Clinical-stage biotech pioneering targeted protein degradation (PROTAC) technology for oncology. Comparable as an emerging oncology company using novel protein-targeting approaches against previously undruggable mechanisms, similar positioning to AecorBio's IREB2/LIP novel target strategy.
  • Kura Oncology: Clinical-stage precision oncology company developing menin inhibitors and farnesyltransferase inhibitors for genetically defined cancers. Comparable as a mid-stage oncology company focused on novel mechanisms in solid tumors, with similar partnership/development model to AecorBio.
  • Tarsus Pharmaceuticals: Late-stage biotech developing novel therapeutic peptides (lotilaner) for ophthalmic and infectious disease indications. Comparable as a peptide-based therapeutics developer with novel mechanism approaches and multi-program pipeline.

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

Aecor Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aecor Bio leadership team

Management profile

Number of profiles

Profiles5 records

Aecor Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aecor Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aecor Bio

What does Aecor Bio do?

AecorBio develops novel peptide therapeutics through a proprietary high-throughput peptide drug discovery platform, with lead candidate FT-002a-O targeting treatment resistance in Castration-Resistant Prostate Cancer (CRPC). The company also has preclinical programs MA-022s (steroid-resistant asthma and EoE) and Peptide-DRD2 (Restless Leg Syndrome and Parkinson's Disease). Revenue is generated through pharmaceutical licensing and co-development partnerships with large pharma companies rather than direct product sales.

Is Aecor Bio a public or private company?

Aecor Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aecor Bio founded?

Aecor Bio was founded in 2023. It employs 1 to 10 people.

Where is Aecor Bio based?

Aecor Bio is headquartered in Menlo Park, United States, in the North America region.

How does Aecor Bio make money?

One revenue line is on record: pharmaceutical Licensing.

Who are Aecor Bio's main competitors?

Direct peers on record are Protagonist Therapeutics, Crinetics Pharmaceuticals, Rhythm Pharmaceuticals, Palatin Technologies, PepGen, ESSA Pharma and Zealand Pharma. Emerging players are Arvinas, Kura Oncology and Tarsus Pharmaceuticals.

Does Aecor Bio have an API?

No public API is recorded for Aecor Bio.

What industry is Aecor Bio in?

Aecor Bio's product category is Peptide Therapeutics / Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DAecorBio Inc. filed a Form D notice with the Securities and Exchange Commission for an exempt equity offering of $2,532,988 under Rule 506(b), with the first sale occurring on August 16, 2025. The biotechnology company, incorporated in Delaware in 2023 and headquartered in Menlo Park, California, has fully sold the offering to 20 investors with no remaining securities to be sold. Bomi Framroze serves as CEO and signed the filing on October 9, 2025.TipranksAecorBio Secures Funding to Advance Prostate Cancer TherapyAecorBio Inc. secured $1.5 million in equity financing to advance its lead peptide candidate FT-002a for advanced prostate cancer. The funding will support completion of investigational work and an FDA IND application by 2026, with preclinical data showing tumor volume reduction. The company is also expanding its pipeline and seeking strategic partnerships.LinkedInHBC’S biotechnology spin out “AecorBio Inc” (formerly known as HBC Immunology Inc), has successfully directly secured a further $1.5M equity investment at +50% valuation of $30M. This is very…AecorBio Inc, a biotechnology spin-out from Hofseth BioCare ASA, has secured an additional $1.5 million in equity investment at a post-money valuation of $30 million. This funding will fully finance the IND-enabling studies required to submit an application to the U.S. Food and Drug Administration for its lead candidate FT-002a by 2026, with clinical trials expected to begin within the next 12 months.